Self-delivering AUMsilence sdASO
Targeted mRNA knockdown, from cell culture to in vivo studies
No lipid-based transfection reagent, electroporation, or viral vector required.
In an animal the same AUMsilence
T cells
CD4+ (naive, activated, memory, exhausted), CD8+ (naive, effector, memory, exhausted), Tregs, Th1, Th2, Th17, Tfh, gd T cells, NKT, MAIT, CAR-T cells, TILs
B cells and NK cells
Naive B cells, Memory B cells, Plasma cells, GC B cells, Primary NK cells (CD56+CD3-), CAR-NK cells
Macrophages, DCs and granulocytes
Monocytes, M1/M2 macrophages, BMDMs, Peritoneal, Alveolar, Kupffer cells, Microglia, TAMs, Myeloid DCs, Plasmacytoid DCs, Neutrophils, Eosinophils, Basophils, Mast cells
Hematopoietic progenitors
Long-term HSCs, Short-term HSCs, CD34+ HSPCs, MPPs, CLPs, CMPs, GMPs, MEPs, AGM embryonic HSCs
Neurons
Cortical, Hippocampal, Motor, Sensory, DRG, Dopaminergic, GABAergic, Glutamatergic, Purkinje, Retinal ganglion, Enteric, iPSC-derived neurons
Glial and neural stem cells
Astrocytes, Oligodendrocytes, Microglia, Schwann cells, hiPSC-derived NSCs, Adult neural progenitors, Hippocampal slices, Brain sections, Spinal cord explants
Cardiovascular
Primary and iPSC cardiomyocytes, HASMCs, HCASMCs, Pulmonary artery SMCs, Endothelial cells (HUVECs, HAECs), Cardiac fibroblasts, Pericytes
Musculoskeletal
Myoblasts, Myotubes, Satellite cells, Osteoblasts, Osteoclasts, Osteocytes, Chondrocytes, Synoviocytes, Tenocytes, MSCs
Stem and progenitor cells
Human ESCs, Mouse ESCs, iPSCs, iPSC-derived neurons, cardiomyocytes, hepatocytes, NSCs, HSCs, CD34+ HSPCs, MSCs, Cardiac and Endothelial progenitors, Intestinal stem cells (Lgr5+)
Liver and gastrointestinal
Primary hepatocytes, Hepatic stellate cells, Cholangiocytes, Intestinal epithelial, Colonocytes, Paneth cells, Goblet cells, Pancreatic beta, ductal, and acinar cells
Lung, airway and kidney
Tracheobronchial epithelial, Alveolar epithelial type I and II, Bronchial epithelial, Airway smooth muscle, Lung fibroblasts, Podocytes, Mesangial cells, Tubular epithelial cells
Skin, eye, reproductive and other
Keratinocytes, Melanocytes, Fibroblasts, CAFs, RPE cells, Corneal epithelial, Trophoblasts, HEK293T, NIH3T3, THP-1, Jurkat, Neuro-2a
- No transfection reagents
- No viral vectors
- No electroporation
- Suspension and adherent cells
Tumor models
Tumor spheroids (any cancer type), Patient-derived tumoroids (CRC, lung, liver, pancreatic, breast, ovarian), PDX-derived organoid cultures, Multicellular tumor microenvironment models, Co-culture systems (immune cells + tumor cells)
CNS organoids
Brain organoids, Cerebral organoids, Spinal cord organoids, Retinal organoids, Cortical organoids, Midbrain organoids
Organ organoids
Intestinal organoids, Kidney organoids, Liver and hepatic organoids, Lung and airway organoids, Cardiac organoids, Gastric organoids, Pancreatic organoids, Prostate organoids
Tissue-engineered models
3D microvasculature (HUVECs on beads), Air-liquid interface (ALI) cultures, Organ-on-chip models, Tissue explant cultures (brain, muscle, AGM), Transwell co-culture and migration systems, Scaffold-based 3D cultures
Solid tumors
Melanoma, Glioblastoma (GBM), DIPG/DMG, Prostate cancer, Breast cancer, Ovarian cancer, NSCLC, SCLC, Hepatocellular carcinoma (HCC), Cholangiocarcinoma, Colorectal cancer, Gastric cancer, Esophageal cancer, Renal cell carcinoma, Bladder cancer, Pancreatic cancer, Head and neck SCC, Thyroid cancer, Sarcomas, Mesothelioma
Hematologic malignancies
Acute lymphoblastic leukemia (B-ALL, T-ALL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, Hodgkin lymphoma, Mantle cell lymphoma, T-cell lymphoma, Multiple myeloma, Thymoma
Patient-derived models
Patient-derived neurospheres (GBM, DMG), Patient-derived tumoroids (CRC, lung, liver, breast), Tumor-infiltrating lymphocytes (TILs) from surgical specimens, Primary cancer cells from patient biopsies, PDX-derived cell cultures
- AUMsilence sdASOs penetrate 3D structures without carriers
- Compatible with organoid protocols
In vivo administration routes
Optimize administration route, formulation, dose, administration volume, and dosing schedule for each study.

Route 1
Intravenous IV
Lateral tail vein
Lateral tail vein: a fine needle nearly parallel to the tail, entering the distal third first.

Route 2
Intraperitoneal IP
Right lower abdominal quadrant
Lower right quadrant of the abdomen, the needle toward the head at 30 to 45 degrees, at most 10 mL/kg.

Route 3
Subcutaneous SC
Dorsolateral flank
Dorsolateral flank: the skin tented, the needle slid under the skin parallel to the back.

Route 4
Intramuscular IM
Proximal quadriceps muscle
Front of the thigh, the quadriceps, clear of the sciatic nerve; a fine needle, tens of microliters.

Route 5
Intrathecal injection IT
Lower lumbar L5-L6 interspace
Lumbar puncture between L5 and L6, a 30-gauge needle, 10 microliters, the tail flick as the sign.

Route 6
Intrathecal catheter IT
Lumbar catheter and dorsal port
A lumbar catheter placed between L5 and L6 and advanced to the lumbar cord, dosed through a dorsal port.
The pictures
- The pictures are the object pictures of AUM BioTech's workflow slide, rendered views of the objects on a white ground. None is a photograph of an experiment and none records a measurement.
- The pictures are rendered illustrations of each procedure, not photographs; the captions describe the procedure.
In vivo delivery, no carrier required
| Delivery route | Description | Research models and targets |
|---|---|---|
| Intraperitoneal (IP) | Systemic peritoneal delivery | Liver, spleen, immune cells, tumor models |
| Intravenous (IV) | Systemic vascular delivery | Liver, spleen, circulating cells, metastasis models |
| Intrathecal | Spinal canal / CSF delivery | Spinal cord injury, ALS, SMA, pain models |
| Stereotaxic (brain) | Direct CNS parenchymal injection | Alzheimer's, Parkinson's, tauopathies, brain tumors |
| Intracerebroventricular | CSF / ventricular delivery | CNS-wide distribution, neurodegenerative diseases |
| Intratumoral | Direct tumor injection | Solid tumors, xenograft models, syngeneic tumors |
| Subcutaneous | Local tissue delivery | Tumor models, fibrosis, local inflammation |
| Intranasal | Non-invasive CNS access | Brain delivery via olfactory route, respiratory targets |
| Intravitreal | Intraocular delivery | Retinal degeneration, macular degeneration, glaucoma |
| Intra-articular | Joint cavity delivery | Osteoarthritis, rheumatoid arthritis |
| Topical / transdermal | Skin surface delivery | Dermatologic conditions, wound healing, psoriasis |
| Ex vivo to transplant | Cell treatment then transfer | HSC transplant, adoptive T cell transfer, CAR-T/NK |
- No delivery vehicle
- No lipid nanoparticles
- No viral vectors
- Direct administration in saline or PBS
Protocol
In vitro workflow
Optimize cell density, AUMsilence sdASO concentration, exposure duration, and assay time point for each model.

Step 1
Prepare cells and AUMsilence sdASO
Plate cells at the optimized density. Reconstitute AUMsilence sdASO in sterile, nuclease-free water or a validated compatible buffer.

Step 2
Add to culture medium
Add AUMsilence sdASO directly to the culture medium at the study concentration.

Step 3
Incubate
Use a model-specific exposure period under standard culture conditions.
- controltreated
Step 4
Quantify knockdown
Quantify target mRNA and, where appropriate, protein abundance or a functional phenotype. Include untreated and non-targeting controls.
Schematic of the three readouts, not data. mRNA by RT-qPCR, protein by immunoblot, protein or phenotype by flow cytometry.